Brief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
22/10/2026 07:33
BRIEF-Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln Oct 22 (Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST:
Q3 2026 NET RESULT WAS -9,488 TSEK
Q3 2026 EPS WAS -1.26 SEK
Q3 2026 OPERATING CASH FLOW WAS -9,954 TSEK
Source text: ID:nMFN8y8Qvf
Further company coverage: ANNX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed